STERIALS

A clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for cardiovascular and pulmonary diseases. The company holds the North American development and commercialization rights to subcutaneous and oral formulations of levosimendan, which it is developing as a treatment for pulmonary hypertension. The company is also developing medicines containing imatinib for the treatment of pulmonary arterial hypertension. The company is based in Delaware.